Accelerating efforts towards elimination and attainment of malaria-free status

MMV and partners work to bring forward medicines which fulfill critical unmet needs in malaria and accelerate efforts towards achieving elimination and malaria-free status. Here are recent key milestones in this area: 

  • Two potent compounds against P. vivax liver stages identified through screening 
  • 6,500 new data points generated from transmission-blocking assays performed in collaboration with Imperial College, London
  • Cipargaminnew formulation for intravenous administration completed Phase II oral malaria patient study, parenteral GLP safety study and first-in-human study with the intravenous formulation
  • Ganaplacide-lumefantrine (frontrunner new combination therapy) progressed to Part B of the Phase IIb trial, with an additional paediatric study (KALUMI) ongoing


Updated June 2021